SCYNEXIS Inc
SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It is developing its antifungal platform fungerps, a class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus genera, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this class of antifungals with additional assets from the fungerp family under development, including SCY-247, which is in clinical stages of development. The United States Food and Drug Administration approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying SCYNEXIS's stock with a target price of $6.67, indicating strong growth potential.
Financial Health
SCYNEXIS Inc is earning revenue and managing costs well, but overall performance is moderate.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SCYX
Targeting Superbugs: The Next Wave Of Antibiotics
GSK's new antibiotic for gonorrhea has received priority review from the FDA, underscoring the urgent need for new antimicrobial treatments. This event signals a potential resurgence in the market for companies developing novel antibiotics to address drug-resistant infections.
Published: August 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline-Driven Value
Company value is heavily influenced by clinical and regulatory milestones, which can create rapid share movement — though outcomes are uncertain.
Specialist Therapeutics
Focus on antifungal treatments targets an underserved area of infectious disease, but commercial uptake and reimbursement are not guaranteed.
Catalysts To Watch
Key catalysts include trial results, approvals and partnerships; monitor cash runway and financing as they affect execution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
